- June 1st, 2017 : Vaxon announces results of its Phase IIb lung cancer trial of Vx-001, a therapeutic vaccine based on optimized cryptic peptides
To download American/english version click here – Version Française
- June 20, 2016 : Vaxon Biotech publishes article supporting potential of proprietary optimized cryptic peptides as ‘universal neoantigens’
To download American/english version click here
- March 16, 2016 : Vaxon Biotech completes enrollment of phase 2b lung cancer trial of first therapeutic vaccine based on optimized cryptic peptides
To download American/english version click here
- June 22, 2015 : VAXON Biotech granted Japanese patent for new cancer vaccine candidates.
To download American/English version click here
- March 30 2015 : VAXON Biotech appoints founder and chief scientific officer, Dr. Kostas Kosmatopoulos, as CEO.
To download American/English version click here
- December 1st, 2014 : VAXON Biotech announces the inclusion of the 110th patients in the phase IIb clinical study with the Vx-001 vaccine in NSCLC.
To download American/English version click here
- September 1st, 2012 :VAXON-Biotech announces that the first patient has been randomized in the multicenter Phase IIb trial (Vx-001-201) for the treatment of non-small-cell lung cancer with the therapeutic cancer vaccine Vx-001.
- February 28th, 2012 : VAXON-Biotech announces that two patent applications covering Vx-001 and Vx-006 vaccines have been granted in China and Japan respectively.
- August 30th, 2011 : VAXON-Biotech announces publication of two articles in Cancer Immunology Immunotherapy and in Annals of Oncology presenting immunological and clinical data in cancer patients vaccinated with Vx-001.
Ann. Oncol., 2012, 23: 442-9
Cancer Immunol. Immunother., 2012, 61: 157-68
- 20/02/09 : VAXON-Biotech’s lead product, Vx-001, has been granted orphan drug status by FDA for the treatment of NSCLC for HLA-A2+ patients with TERT+ tumours.
- 30/05/08 : VAXON-Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the ASCO 2008 Annual Meeting.
To download ASCO 2008 Abstract click here
- 11/04/08 : VAXON-Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the 99th AACR Annual Meeting.
To download American / English version click here
- 16/11/07 : VAXON-Biotech Receives from EMA an European Orphan Medicinal Product Designation for Vx-001.
To download American / English version click here / Télécharger la version française en cliquant ici
- 02/07/07 : VAXON-Biotech publishes encouraging results in the Journal of Clinical Oncology for the treatment of Non-Small Cell Lung Cancer with Vx-001.
To download American / English version click here
- 03/06/07 : VAXON-Biotech Presents Preliminary Results from Vx-001 Vaccine Clinical Trial on Lung Cancer at the ASCO 2007 annual meeting.
To download American / English version click here
- 03/04/06 : VAXON-Biotech and Institut Pasteur Announce Collaboration to Develop New Products and Models for Cancer Immunotherapy.
To download American / English version click here
- 14/03/06 : VAXON-Biotech to Present Latest Clinical Data of its Vx-001 Cancer Vaccine at the 97thAACR Annual Meeting.
To download American / English version click here